Search - tctmd.com

Displaying 21 - 40 of 95

Sort: Relevancy | Date

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Conference News LINC 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

L.A. McKeown

June 09, 2023

News Daily News

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

L.A. McKeown

March 29, 2023

News Daily News

Only Half of Revascularized PAD Patients Receive GDMT

L.A. McKeown

February 14, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Daily News

Worse Complications After PVI in Women Highlight Research Gaps

L.A. McKeown

August 16, 2022

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

L.A. McKeown

April 04, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Daily News

LITE: High- Beats Low-Intensity Exercise at Home for Improving PAD

L.A. McKeown

April 09, 2021

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

L.A. McKeown

November 11, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

L.A. McKeown

October 18, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

L.A. McKeown

August 12, 2020

News Daily News

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

L.A. McKeown

July 02, 2020

Advertisement

October 2023 News Roundup

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

Only Half of Revascularized PAD Patients Receive GDMT

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

Worse Complications After PVI in Women Highlight Research Gaps

High Lp(a) May Predict Risk of CV and Limb Events in PAD

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

LITE: High- Beats Low-Intensity Exercise at Home for Improving PAD

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content